Ionis Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 02/01/2023
Ionis Pharmaceuticals Stock Forecast and Price Target
The average price target of $50.00 for Ionis Pharmaceuticals's stock set by six distinguished analysts in recent weeks would represent a potential upside of approximately 25.41% from the last closing price in January, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $92.00 and a low estimate of $26.00. If you are interested in IONS stock, it is important to also consider its competitors.
25.41% Upside
Ionis Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's Price has decreased by 62.56% In the last two years, from $32.85 to $12.30. In the next year, analysts predict that Fair Value will jump to $30.35 – up 146.78% from the current level. Looking ahead to nine years, experts forecast that Fair Value will grow by 1276.11%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.16 | $53.97 | 19.23% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$271.73 | $268.00 | 2.31% |
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | 108.44€ | 20.72% |
| MRNA Stock Forecast | Moderna | Outperform |
11
|
$176.06 | $0.00 | 21.27% |
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | ¥0.00 | 35.30% |
Ionis Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's Revenue has decreased by 27.81% In the last two years, from $1.12B to $810.46M. In the next year, analysts predict that Revenue will jump to $902.04M – up 11.30% from the current level. Looking ahead to nine years, experts forecast that Revenue will grow by 10.87%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals | Outperform |
7
|
$226.40 | $244.18 | 10.87% |
| SGEN Stock Forecast | Seagen | Outperform |
6
|
$139.48 | $167.40 | 11.13% |
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$115.35 | $115.45 | 4.03% |
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| INCY Stock Forecast | Incyte | Outperform |
9
|
$85.14 | $88.18 | 1.01% |
| SRPT Stock Forecast | Sarepta Therapeutics | Outperform |
6
|
$124.97 | $139.65 | 21.63% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$158.79 | $0.00 | 25.95% |
Ionis Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Ionis Pharmaceuticals's Free Cash Flow has decreased by 94.01%, from $314.72M to $18.84M. In the coming year, analysts are expecting an increase in Free Cash Flow, predicting it will reach $2.57B – an increase of 13526.97%. Over the next nine years, experts anticipate that Free Cash Flow growth for Ionis Pharmaceuticals will be 411619284.33%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| EXEL Stock Forecast | Exelixis | Outperform |
16
|
$17.62 | $26.06 | 41.88% |
| 4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥7.07k | ¥0.00 | 55.59% |
| DCPH Stock Forecast | Deciphera Pharmaceuticals | Hold |
6
|
$17.01 | $0.00 | -41.21% |
Ionis Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Ionis Pharmaceuticals has seen a decline in its Net Income, from $278.14M to $-28.60M – a 110.28% decrease. In the next year, analysts believe that Net Income will reach $-321.21M – an increase of 1023.11%. For the next nine years, the forecast is forNet Income to grow by 34621.13%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| STOK Stock Forecast | Stoke Therapeutics | Buy |
4
|
$9.95 | $61.44 | 422.61% |
| DYN Stock Forecast | Dyne Therapeutics | Buy |
5
|
$14.61 | $0.00 | 57.43% |
| ABUS Stock Forecast | Arbutus Biopharma | Outperform |
9
|
$3.01 | $8.29 | 156.81% |
Ionis Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Ionis Pharmaceuticals's EBITDA has fallen from $382.56M to $14.26M – a 96.27% decrease. According to 0 prominent analysts, Ionis Pharmaceuticals's EBITDA will fall by 526.17% in the next year, reaching $-60.77M. By 2030, professionals believe that Ionis Pharmaceuticals's EBITDA will decrease by 679.42%, reaching $-82.63M – a concerning trend for the company.
Ionis Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's EBIT has decreased In the last two years, from $368.11M to $-3.58M – a 100.97% drop. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $-100.36M – an increase of 2703.34%. The Ionis Pharmaceuticals forecast is for EBIT to reach $-76.25B or grow by 2129808.58%.
Ionis Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's EPS has decreased by 62.56% In the last two years, from $2.19 to $0.82. In the next year, analysts predict that EPS will jump to $2.02 – up 146.78% from the current level. Looking ahead to nine years, experts forecast that EPS will grow by 1276.11%.